Search Results - "Duncan, Daniel L."

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases by Huang, Richard S.P., Haberberger, James, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Ferguson, Naomi Lynn, Williams, Erik, Elvin, Julia, Vergilio, Jo-Anne, Killian, Jonathan Keith, Lin, Douglas I., Tse, Julie, Hiemenz, Matthew, Owens, Clarence, Danziger, Natalie, Hegde, Priti S., Venstrom, Jeffrey, Alexander, Brian, Ross, Jeffrey S., Ramkissoon, Shakti H.

“…PD-L1 immunohistochemistry (IHC) currently has the most Food and Drug Administration (FDA) approvals as a companion diagnostic (CDx) for immunotherapies in…”
Get full text

Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy by Ebot, Ericka M., Duncan, Daniel L., Tolba, Khaled, Fabrizio, David, Frampton, Garrett M., Comment, Leah A., Albacker, Lee A.

“…NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) patients without targetable driver alterations includes…”
Get full text

Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma by Huang, Richard S.P., Haberberger, James, Murugesan, Karthikeyan, Danziger, Natalie, Hiemenz, Matthew, Severson, Eric, Duncan, Daniel L., Ramkissoon, Shakti H., Ross, Jeffrey S., Elvin, Julia A., Lin, Douglas I.

“…Positive program death-ligand 1 (PD-L1) immunohistochemistry (IHC) is an approved companion diagnostic guiding the use of immune checkpoint inhibitors in…”
Get full text

Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD‐L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer by Huang, Richard S.P., Li, Xinyan, Haberberger, James, Sokol, Ethan, Severson, Eric, Duncan, Daniel L., Hemmerich, Amanda, Edgerly, Claire, Williams, Erik, Elvin, Julia, Vergilio, Jo‐Anne, Killian, Jonathan Keith, Lin, Douglas, Hiemenz, Matthew, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Danziger, Natalie, Erlich, Rachel, Frampton, Garrett, Cohen, Michael B., McGregor, Kimberly, Reddy, Prasanth, Cardeiro, Dawn, Anhorn, Rachel, Venstrom, Jeffrey, Alexander, Brian, Brown, Charlotte, Pusztai, Lajos, Ross, Jeffrey S., Ramkissoon, Shakti H.

“…Background We examined the current biomarker landscape in breast cancer when programmed death‐ligand 1 (PD‐L1) testing is integrated with comprehensive genomic…”
Get full text

Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns by Treece, Amanda L, Duncan, Daniel L, Tang, Weihua, Elmore, Sandra, Morgan, Douglas R, Dominguez, Ricardo L, Speck, Olga, Meyers, Michael O, Gulley, Margaret L

“…MicroRNA expression in formalin-fixed paraffin-embedded tissue (FFPE) or plasma may add value for cancer management. The GastroGenus miR Panel was developed to…”
Get full text

Clinicopathologic and Genomic Characterization of PD‐L1 Positive Urothelial Carcinomas by Huang, Richard S.P., Haberberger, James, Harries, Lukas, Severson, Eric, Duncan, Daniel L., Ferguson, N. Lynn, Hemmerich, Amanda, Edgerly, Claire, Murugesan, Karthikeyan, Xiao, Jinpeng, McEwan, Deborah, Holmes, Oliver, Hiemenz, Matthew, Venstrom, Jeffrey, Elvin, Julia A., Creeden, James, Lin, Douglas I., Ross, Jeffrey S., Ramkissoon, Shakti H.

“…Introduction Pembrolizumab was approved with an accompanying companion diagnostic (CDx) assay (PD‐L1 DAKO 22C3) for urothelial carcinoma (UC). In this study,…”
Get full text

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry by Huang, Richard S P, Severson, Eric, Haberberger, James, Duncan, Daniel L, Hemmerich, Amanda, Edgerly, Claire, Ferguson, N Lynn, Frampton, Garrett, Owens, Clarence, Williams, Erik, Elvin, Julia, Vergilio, Jo-Anne, Killian, Jonathan Keith, Lin, Douglas, Morley, Samantha, McEwan, Deborah, Holmes, Oliver, Danziger, Natalie, Cohen, Michael B, Sathyan, Pratheesh, McGregor, Kimberly, Reddy, Prasanth, Venstrom, Jeffrey, Anhorn, Rachel, Alexander, Brian, Brown, Charlotte, Ross, Jeffrey S, Ramkissoon, Shakti H

“…Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC)…”
Get full text

Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay by Cotten, Steven W., Duncan, Daniel L., Burch, Elizabeth A., Seashore, Carl J., Hammett-Stabler, Catherine A.

“…The results of newborn drug screening have far-reaching impact not only in healthcare, but also in the legal domain. Therefore, the accuracy of these results…”
Get full text

Pre-Phase Chemotherapy for Acute Lymphoblastic Leukemia: A Cautionary Tale by Arreola, Alexandra, Coward, Wilborn, Duncan, Daniel L, Rao, Kathleen W

Get full text

Assessing Measurable Residual Disease in Acute Myeloid Leukemia by Duncan, Daniel L., MD, Zeidner, Joshua F., MD, Montgomery, Nathan D., MD, PhD

Get full text

Displaced Granulosa Cells in the Fallopian Tube Mistaken for Metastatic Granulosa Cell Tumor by Duncan, Daniel L, Rambally, Brooke S, Lininger, Ruth A, DiFurio, Megan J

“…A 44-yr-old woman underwent a total hysterectomy and bilateral salpingectomy secondary to uterine leiomyomas. Gross examination of the fallopian tubes revealed…”
Get full text

39 - Pre-Phase Chemotherapy for Acute Lymphoblastic Leukemia: A Cautionary Tale by Arreola, Alexandra, Coward, Wilborn, Duncan, Daniel L., Rao, Kathleen W.

Get full text

Response to Mays and McCarthy by Hammett-Stabler, Catherine A., Cotten, Steven W., Duncan, Daniel L., Burch, Elizabeth A., Seashore, Carl J.

Get full text